The disclosed subject matter provides for vaccines against coronaviruses comprising one or more fungal cells genetically engineered to secrete an antigen derived from a coronavirus, e.g., SARS-CoV-2, in situ, and methods of use thereof.

The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.

The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.

Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.

The invention provides a SARS-CoV-2 mucosal vaccine composition, preparation, and use thereof. The SARS-CoV-2 mucosal vaccine composition comprises an antigen fusion protein which includes a SARS-CoV-2 antigen and a Type IIb heat-labile enterotoxin A subunit from Escherichia coli. Immunization with the antigen fusion protein elicits cellular and humoral immune responses, including systemic and mucosal immune responses, against SARS-CoV-2 in a subject, and thus protects the subject from viral infection.

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.

A method of treating a viral infection in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of cell-derived vesicles comprising wild-type p53. Methods of inducing cell cycle arrest and/or apoptosis of a virally infected cell are also disclosed.

Disclosed are influenza virus-like particles (VLPs), wherein the VLPs include hemagglutinin (HA) protein and neuraminidase (NA) protein on the surface of the VLPs, a nucleoprotein (NP) ribonucleoprotein complex, and wherein the VLPs do not contain a ribonucleoprotein complex of at least one of PB1, PB2, and NS.

The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.